Anaphylaxis: assessment and referral after emergency treatment: Draft for consultation
Open for comments Open until Request commenting lead permission
We have updated this service so that members of the same organisation can now collaborate on a joint online response.
Read our blog to learn more.
Overview
This guideline covers assessment and referral for anaphylaxis. It aims to improve the quality of care for people with suspected anaphylaxis by detailing the assessments that are needed and recommending referral to specialist allergy services.
NICE has also produced a guideline on drug allergy.
This guideline will update NICE guideline CG134 (published 2011, amended 2020).
Who is it for?
Healthcare professionals
Commissioners and providers
People with suspected anaphylaxis and their families and carers
What does it include?
the recommendations
the guideline context.
New and updated recommendations
We have updated the recommendations on period of observation following treatment for suspected anaphylaxis to bring them in line with guidance from the Resuscitation Council UK.
We have also updated 2 recommendations on admission and referral for consistency with the new recommendations on observation following treatment and to incorporate advice from the MHRA and the British Society for Allergy and Clinical Immunology (BSACI), on the provision of autoinjectors. You are invited to comment on the new and updated recommendations by answering the questions on the consultation page. New recommendations are marked as [2026].
We have also made some minor changes to the structure of the guideline, including introducing sub-headings to improve navigation.
See update information for a full explanation of what is being updated.
This guideline covers assessment and referral for anaphylaxis. It aims to improve the quality of care for people with suspected anaphylaxis by detailing the assessments that are needed and recommending referral to specialist allergy services. NICE has also produced a guideline on drug allergy. This guideline will update NICE guideline CG134 (published 2011, amended 2020). Who is it for?
What does it include?
New and updated recommendations We have updated the recommendations on period of observation following treatment for suspected anaphylaxis to bring them in line with guidance from the Resuscitation Council UK. We have also updated 2 recommendations on admission and referral for consistency with the new recommendations on observation following treatment and to incorporate advice from the MHRA and the British Society for Allergy and Clinical Immunology (BSACI), on the provision of autoinjectors. You are invited to comment on the new and updated recommendations by answering the questions on the consultation page. New recommendations are marked as [2026]. We have also made some minor changes to the structure of the guideline, including introducing sub-headings to improve navigation. See update information for a full explanation of what is being updated. |
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions